Phase I study of erlotinib (tarceva) and temsirolimus (CCI-779) for patients with recurrent malignant gliomas (NABTC 04-02) Conference

Wen, PY, Chang, SM, Kuhn, J et al. (2006). Phase I study of erlotinib (tarceva) and temsirolimus (CCI-779) for patients with recurrent malignant gliomas (NABTC 04-02) . NEURO-ONCOLOGY, 8(4), 454-454.

cited authors

  • Wen, PY; Chang, SM; Kuhn, J; Lamborn, K; Robins, HI; Cloughesy, T; Gilbert, MR; Yung, WKA; Mehta, M; DeAngelis, LM; Abrey, LE; Kesari, S; Drappatz, J; Lassman, AB; Dancey, J; Prados, MD

sustainable development goals

authors

date/time interval

  • September 14, 2006 -

publication date

  • October 1, 2006

webpage

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology

Location

  • Vienna, AUSTRIA

Conference

  • 7th Congress of the European-Association-for-Neuro-Oncology (EANO)

publisher

  • DUKE UNIV PRESS

start page

  • 454

end page

  • 454

volume

  • 8

issue

  • 4